Impact of antiretroviral medications on fasting lipid parameters

Rev Cardiovasc Med. 2014:15 Suppl 1:S30-7.

Abstract

It is widely accepted that metabolic disease in human immunodeficiency virus (HIV) develops at the intersection of traditional risk factors and HIV-specific contributors, but in observational studies it is difficult to dissect the contribution of the two. This review describes the metabolic impact of antiretroviral medications recommended in the first-line treatment in HIV-infected naive patients. At a clinical level, coronary heart disease screening and management will continue to be of paramount importance in the long-term management of HIV-positive patients on antiretroviral therapy.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Anti-Retroviral Agents / adverse effects*
  • Biomarkers / blood
  • Coronary Disease / blood
  • Coronary Disease / etiology
  • Coronary Disease / virology
  • Dyslipidemias / blood
  • Dyslipidemias / chemically induced*
  • Dyslipidemias / drug therapy
  • Dyslipidemias / virology
  • HIV Infections / blood
  • HIV Infections / drug therapy*
  • HIV Infections / virology
  • HIV Long-Term Survivors
  • Humans
  • Lipid Metabolism / drug effects*
  • Lipids / blood*
  • Prognosis
  • Risk Factors
  • Time Factors

Substances

  • Anti-Retroviral Agents
  • Biomarkers
  • Lipids